Effect of Cyclosporine and Tacrolimus on Cytochrome P450 Activities in Human Liver Microsomes

DOI Web Site Web Site 被引用文献5件 参考文献65件
  • 丹羽 俊朗
    アステラス製薬株式会社　育薬研究所
  • 山本 幸子
    アステラスリサーチサービス株式会社　育薬研究所
  • 斎藤 美穂
    アステラスリサーチサービス株式会社　育薬研究所
  • 白神 歳文
    アステラス製薬株式会社　代謝研究所
  • 高木 明
    アステラス製薬株式会社　育薬研究所

この論文をさがす

抄録

  The effects of cyclosporine and tacrolimus on cytochrome P450 (CYP) 1A2-mediated 7-ethoxyresorufin O-deethylation, CYP2C9-mediated tolbutamide hydroxylation, CYP2C19-mediated S-mephenytoin 4′-hydroxylation, CYP2D6-mediated debrisoquine 4-hydroxylation, CYP2E1-mediated chlorzoxazone 6-hydroxylation, CYP3A4-mediated nifedipine oxidation, and CYP3A4-mediated testosterone 6β-hydroxylation activities in human liver microsomes were compared. Cyclosporine and tacrolimus, at concentrations of 0.2 or 2 μM, neither inhibited nor stimulated any of the metabolic activities except for those of CYP3A4. On the other hand, cyclosporine and tacrolimus competitively inhibited CYP3A4-mediated nifedipine oxidation activity, with inhibition constants (Ki) of 1.42 and 0.36 μM, respectively. In addition, 20 μM cyclosporine inhibited CYP2C19 and CYP2D6 activities by 29% and 30%, respectively. These results suggest that tacrolimus would not cause clinically significant interactions with other drugs, which are metabolized by CYPs, via the inhibition of hepatic metabolism and that the reason why cyclosporine, but not tacrolimus, has a pharmacokinetic inhibitory effect might be that the dosage and/or the unbound concentrations around its metabolic enzymes are higher than those of tacrolimus, rather than the differences in the inhibition potential. Obvious substrate-dependent effects on CYP3A4-inhibition potential were not observed.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 127 (1), 209-216, 2007

    公益社団法人 日本薬学会

被引用文献 (5)*注記

もっと見る

参考文献 (65)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ